These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36726537)

  • 1. High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May-October 2021) in Matadi, Democratic Republic of the Congo.
    Munyeku-Bazitama Y; Okitale-Talunda P; Mpingabo-Ilunga P; Yambayamba MK; Tshiminyi PM; Umba-Phuati A; Kimfuta J; Phukuta FA; Makindu G; Mufwaya-Nsene R; Asari R; Makimoto S; Baketana LK; Ahuka-Mundeke S; Isono M; Nsio-Mbeta J; Makiala-Mandanda S; Muyembe-Tamfum JJ
    Open Forum Infect Dis; 2023 Jan; 10(1):ofad023. PubMed ID: 36726537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020-April 2021), Democratic Republic of the Congo.
    Munyeku-Bazitama Y; Folefack GT; Yambayamba MK; Tshiminyi PM; Kazenza BM; Otshudiema JO; Guinko NT; Umba MD; Mulumba A; Baketana LK; Mukadi PK; Smith C; Muyembe-Tamfum JJ; Ahuka-Mundeke S; Makiala-Mandanda S
    Emerg Infect Dis; 2023 Jan; 29(1):89-97. PubMed ID: 36573545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Prevalence of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (Anti-SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey.
    Nkuba AN; Makiala SM; Guichet E; Tshiminyi PM; Bazitama YM; Yambayamba MK; Kazenza BM; Kabeya TM; Matungulu EB; Baketana LK; Mitongo NM; Thaurignac G; Leendertz FH; Vanlerberghe V; Pelloquin R; Etard JF; Maman D; Mbala PK; Ayouba A; Peeters M; Muyembe JT; Delaporte E; Ahuka SM
    Clin Infect Dis; 2022 Mar; 74(5):882-890. PubMed ID: 34089598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of COVID-19 infection in a densely populated district in the eastern Democratic Republic of Congo.
    Irenge LM; Bulakali HM; Akonkwa AI; Ambroise J; Gala JL
    Epidemiol Infect; 2023 Feb; 151():e24. PubMed ID: 36775822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of Bas-Congo virus in Mangala, Democratic Republic of the Congo: a population-based cross-sectional study.
    Munyeku-Bazitama Y; Okitale-Talunda P; Hattori T; Saito T; Lombe BP; Miyamoto H; Mori-Kajihara A; Kajihara M; Nkoy AB; Twabela AT; Masumu J; Ahuka-Mundeke S; Muyembe-Tamfum JJ; Igarashi M; Park ES; Morikawa S; Makiala-Mandanda S; Takada A
    Lancet Microbe; 2024 Jun; 5(6):e529-e537. PubMed ID: 38555924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epidemiological characteristics of the Covid-19 epidemic between 2020 and 2022 in Kongo central, DRC].
    Akinocho EM; Kasongo M; Moerman K; Sere F; Coppieters Y
    Med Trop Sante Int; 2023 Jun; 3(2):. PubMed ID: 37525685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of anti-SARS-CoV-2 antibodies in people attending the two main Goma markets in the eastern Democratic Republic of the Congo.
    Mitangala PN; Irenge LM; Musubao ET; Kahindo JBM; Ayonga PN; Kyembwa Safari I; Kubuya JB; Ntabe EN; Kabangwa Senga RK; Mutombo GN; Ambroise J; Gala JL
    Epidemiol Infect; 2023 Sep; 151():e167. PubMed ID: 37724000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroprevalence of anti-SARS-CoV-2 IgG Antibodies in the Staff of a Public School System in the Midwestern United States.
    Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
    medRxiv; 2020 Oct; ():. PubMed ID: 33140066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020.
    Talla C; Loucoubar C; Roka JL; Barry MA; Ndiaye S; Diarra M; Thiam MS; Faye O; Dia M; Diop M; Ndiaye O; Tall A; Faye R; Mbow AA; Diouf B; Diallo JP; Keita IM; Ndiaye M; Woudenberg T; White M; Ting J; Diagne CT; Pasi O; Diop B; Sall AA; Vigan-Womas I; Faye O
    IJID Reg; 2022 Jun; 3():117-125. PubMed ID: 35720135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Following the Largest Initial Epidemic Wave in the United States: Findings From New York City, 13 May to 21 July 2020.
    Pathela P; Crawley A; Weiss D; Maldin B; Cornell J; Purdin J; Schumacher PK; Marovich S; Li J; Daskalakis D;
    J Infect Dis; 2021 Jul; 224(2):196-206. PubMed ID: 33836067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ) IgG-antibody seroprevalence among quarantined population, during the first wave of COVID-19 pandemic, In North West Ethiopia (from 30 April to 30 May 2020).
    Kebede F; Kebede T; Kebede B
    SAGE Open Med; 2022; 10():20503121221076931. PubMed ID: 35154744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of the use of contraceptive methods by adolescents in the Democratic Republic of the Congo: results of a cross-sectional survey.
    Mpunga DM; Chenge FM; Mambu TN; Akilimali PZ; Mapatano MA; Wembodinga GU
    BMC Womens Health; 2022 Nov; 22(1):478. PubMed ID: 36437443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study.
    Rouge Elton PA; Schmitt PA; Faouzi M; Zimmermann P; Ritter Schenk C
    Swiss Med Wkly; 2022 May; 152():w30173. PubMed ID: 35748747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020-May 2021.
    Couture A; Lyons BC; Mehrotra ML; Sosa L; Ezike N; Ahmed FS; Brown CM; Yendell S; Azzam IA; Katić BJ; Cope A; Dickerson K; Stone J; Traxler LB; Dunn JR; Davis LB; Reed C; Clarke KEN; Flannery B; Charles MD
    Open Forum Infect Dis; 2022 Mar; 9(3):ofac044. PubMed ID: 35198651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic.
    Palmateer NE; Dickson E; Furrie E; Godber I; Goldberg DJ; Gousias P; Jarvis L; Mathie L; Mavin S; McMenamin J; McNeilly TN; Murcia P; Murray J; Reid G; Robertson C; Templeton K; von Wissmann B; Wallace LA; Waugh C; McAuley A
    Public Health; 2021 Sep; 198():102-105. PubMed ID: 34411992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Seroprevalence in Delhi, India, During September-October 2021: A Population-Based Seroepidemiological Study.
    Sharma P; Basu S; Mishra S; Gupta E; Agarwal R; Kale P; Mundeja N; Charan BS; Singh G; Singh M
    Cureus; 2022 Jul; 14(7):e27428. PubMed ID: 36051724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Saliva-Based Serological and Behavioral Analysis of SARS-CoV-2 Antibody Prevalence in Howard County, Maryland.
    Brown AC; Koshute PT; Cowley HP; Robinette MS; Gravelyn SR; Patel SV; Ju EY; Frommer CT; Zambidis AE; Schneider EJ; Zhao MY; Mugo BK; Clarke W; Kruczynski K; Pisanic N; Heaney CD; Colella TA
    Microbiol Spectr; 2023 Aug; 11(4):e0276522. PubMed ID: 37289070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroprevalence survey of anti-SARS-CoV-2 antibody and associated factors in South Africa: Findings of the 2020-2021 population-based household survey.
    Moyo S; Simbayi LC; Zuma K; Zungu N; Marinda E; Jooste S; Ramlagan S; Fortuin M; Singh B; Mabaso M; Reddy T; Parker WA; Naidoo I; Manda S; Goga A; Ngandu N; Cawood C; Moore PL; Puren A
    PLOS Glob Public Health; 2023; 3(9):e0002358. PubMed ID: 37747851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.